title: Expression and methylation status of tissue factor pathway inhibitor-2 gene in non-small-cell lung cancer.
abstract: Tissue factor pathway inhibitor-2 (TFPI-2) is a Kunitz-type serine proteinase inhibitor that inhibits plasmin-dependent activation of several metalloproteinases. Downregulation of TFPI-2 could thus enhance the invasive potential of neoplastic cells in several cancers, including lung cancer. In this study, TFPI-2 mRNA was measured using a real-time PCR method in tumours of 59 patients with non-small-cell lung cancer (NSCLC). Tumour TFPI-2 mRNA levels appeared well correlated with protein expression evaluated by immunohistochemistry and were 4-120 times lower compared to those of nonaffected lung tissue in 22 cases (37%). Hypermethylation of the TFPI-2 gene promoter was demonstrated by restriction enzyme-polymerase chain reaction in 12 of 40 cases of NSCLC (30%), including nine of 17 for whom tumour TFPI-2 gene expression was lower than in noncancerous tissue. In contrast, this epigenetic modification was shown in only three of 23 tumours in which no decrease in TFPI-2 synthesis was found (P=0.016). Decreased TFPI-2 gene expression and hypermethylation were more frequently associated with stages III or IV NSCLC (eight out of 10, P=0.02) and the TFPI-2 gene promoter was more frequently hypermethylated in patients with lymph node metastases (eight out of 16, P=0.02). These results suggest that silencing of the TFPI-2 gene by hypermethylation might contribute to tumour progression in NSCLC.
authors.affiliation: INSERM U 618 Protéases et Vectorisation Pulmonaires and IFR 135 Faculté de Médecine, 2 bis Bd Tonnellé, 37032 Tours Cedex, France.
authors.forename: J
authors.initials: J
authors.lastname: Rollin
authors.forename: S
authors.initials: S
authors.lastname: Iochmann
authors.forename: C
authors.initials: C
authors.lastname: Bléchet
authors.forename: F
authors.initials: F
authors.lastname: Hubé
authors.forename: S
authors.initials: S
authors.lastname: Régina
authors.forename: S
authors.initials: S
authors.lastname: Guyétant
authors.forename: E
authors.initials: E
authors.lastname: Lemarié
authors.forename: P
authors.initials: P
authors.lastname: Reverdiau
authors.forename: Y
authors.initials: Y
authors.lastname: Gruel
mesh_terms: D000328:Adult; D000368:Aged; D002289:Carcinoma, Non-Small-Cell Lung / Q000235:genetics* / Q000378:metabolism / Q000473:pathology; D019175:DNA Methylation; D018076:DNA, Complementary / Q000138:chemical synthesis; D004273:DNA, Neoplasm / Q000378:metabolism*; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006023:Glycoproteins / Q000235:genetics*; D006801:Humans; D015151:Immunoblotting; D007150:Immunohistochemistry; D008175:Lung Neoplasms / Q000235:genetics* / Q000378:metabolism / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D016133:Polymerase Chain Reaction; D011446:Prospective Studies; D012333:RNA, Messenger / Q000378:metabolism; D012334:RNA, Neoplasm / Q000378:metabolism
chemical_list: D018076:DNA, Complementary; D004273:DNA, Neoplasm; D006023:Glycoproteins; D012333:RNA, Messenger; D012334:RNA, Neoplasm; C021240:tissue-factor-pathway inhibitor 2